Similarly, other inhibitors of DDR proteins, such as ATM, CHEK1/2, WEE1 and DNA-PK, are currently being evaluated in early-phase clinical trials in solid tumors including NSCLC, and are summarized in Supplementary Table S1. Here, ATM is linked to non-small cell lung carcinoma.